

REMARKS

Claims 1-30 are currently pending in the subject application. Several paragraphs of the Specification and the claims are amended to refer to SEQ ID NOS from the sequence listing.

I. Election/Restriction Requirement

The Examiner is imposing a Restriction/Election Requirement on the claims, categorizing the claims as follows:

Group I: Claims 1-21, drawn to a pharmaceutical composition comprising a caspase inhibitor and/or a compound of the formula R-Lys-X other than a hemocompatibly coated medical product.

Group II: Claims 22-30, drawn to a hemocompatibly coated medical product, coated with a caspase inhibitor and/or a compound of the formula R-Lys-X and a method of making the product.

Applicant elects Group II (hemocompatibly coated medical products) for examination. Claims 22-30 read on elected Group II.

The Examiner is also imposing a Restriction/Election Requirement on the claims, requiring the choice of a caspase inhibitor from those of claim 2. Applicant elects with traverse the caspase inhibitor acetyl-Tyr-Val-Ala-Asp-chloromethyl-ketone (Ac-YVAD-CMK) for examination. Claims 22-27 and 29-30 read on the elected species Ac-YVAD-CMK.

Finally, the Examiner is imposing a Restriction/Election Requirement on the claims, requiring the choice of a compound of formula R-Lys-X. Applicant elects with traverse the species SYSMEHFRWGKPV (SEQ ID NO: 64) as the R-Lys-X formula for examination. Claims 22-30 read on the elected species SYSMEHFRWGKPV. SEQ ID NO: 64 is described in the Specification on page 8, line 1.

II. Sequence Listing

The Examiner states that several amino acid sequences appearing in claims 2, 4 and 7 and on pages 3-5, 7, 19 and 20 of the Specification do not have sequence identifiers. The Sequence Listing is amended to include the following sequence identifiers for species referenced in the Office Action dated July 15, 2010:

Seq ID No.	caspase inhibitor or compound R-Lys-X
64	SYSMEHFRWGKPV
65	Ac-His-Phe-Arg-Lys-Pro-Asp-CMK
66	Ile-Glu-Thr-Asp-fluoromethyl ketone
67	Ac-DEVD-CHO
68	acetyl-Asp-Glu-Val-Asp-fluoromethyl-ketone (Ac-DEVD-FMK)
69	acetyl-Tyr-Val-Ala-Asp-chloromethyl-ketone (Ac-YVAD-CMK)
70	z-DEVD-fmk
71	benzyloxycarbonyl-Asp(OCH ₃)-Glu(OCH ₃)-Val-Asp(OCH ₃)-CH ₂ -fluoromethyl ketone
72	z-IETD-fmk
73	Z-VDVAD-fmk
74	His-Phe-Arg-Trp
75	R''-His-Phe-Arg-Trp-R'-Lys-X
76	R''-His-Phe-Arg-Trp-R'-Lys-Pro-X'
77	R''-His-Phe-Arg-Trp-R'-Lys-Pro-Thr-X'
78	R''-His-Phe-Arg-Trp-R'-Lys-Pro-Val-X'
79	R''-Phe-Arg-Trp-R'-Lys-X
80	R''-Phe-Arg-Trp-R'-Lys-Pro-X'
81	R''-Phe-Arg-Trp-R'-Lys-Pro-Thr-X'
82	R''-Phe-Arg-Trp-R'-Lys-Pro-Val-X'
83	R''-His-Phe-Arg-R'-Lys-X
84	R''-His-Phe-Arg-R'-Lys-Pro-X'
85	R''-His-Phe-Arg-R'-Lys-Pro-Thr-X'
86	R''-His-Phe-Arg-R'-Lys-Pro-Val-X'

Appropriate amendments to the claims and Specification are made herein. As such, it is believed that the claims and Specification are in compliance with the requirements of 37 CFR 1.182 through 1.825.

If any additional fees are due in connection with this document, the Commissioner is authorized to charge those fees to Deposit Account No. 50-1063.

Should the Examiner believe a telephone interview would be helpful to expedite favorable prosecution, the Examiner is invited to contact applicants' undersigned representative at the telephone number listed below.

Respectfully submitted,

TUROC & WATSON, LLP

/Greg Turocy/

Gregory Turocy

Reg. No. 36,952

57TH Floor, Key Tower
127 Public Square
Cleveland, Ohio 44114
Telephone (216) 696-8730
Facsimile (216) 696-8731